AR078775A1 - Composicion farmaceutica que comprende un compuesto indol - Google Patents

Composicion farmaceutica que comprende un compuesto indol

Info

Publication number
AR078775A1
AR078775A1 ARP100103924A ARP100103924A AR078775A1 AR 078775 A1 AR078775 A1 AR 078775A1 AR P100103924 A ARP100103924 A AR P100103924A AR P100103924 A ARP100103924 A AR P100103924A AR 078775 A1 AR078775 A1 AR 078775A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycle
heteroaryl
alkoxy
indicates
Prior art date
Application number
ARP100103924A
Other languages
English (en)
Inventor
Kwang Min Park
Hyoung Jin Kim
Hyo Shin Kwak
Du Hee Park
Hyun Jai Cho
Ji Hyun Kim
Sun Young Koo
Soon Ha Kim
Hyo Soo Kim
Heui Sul Park
Ju Young Kim
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR078775A1 publication Critical patent/AR078775A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Composicion farmacéutica que comprende un compuesto de formula (1), (2) o (3) tal como se define en la memoria descriptiva, para la prevencion o el tratamiento de enfermedades asociadas al estrés oxidativo, la disfuncion mitocondrial, la lesion hipoxica, la necrosis y/o la lesion por reperfusion isquémica, y a una composicion cosmética que comprende un compuesto indol que posee un efecto antioxidante. Reivindicacion 1: Una composicion farmacéutica para la prevencion o el tratamiento de enfermedades asociadas al estrés oxidativo, que comprende una cantidad terapéuticamente eficaz de un compuesto de las formulas (1), (2) o (3) que aparecen más abajo, su sal o isomero farmacéuticamente aceptable como ingrediente activo; y un portador farmacéuticamente aceptable: en la formula (1), na indica un numero que oscila entre 0 y 3, Aa representa heteroarilo o heterociclo de 5 miembros, cada uno de los cuales tiene entre 1 y 3 heteroátomos seleccionados entre N, O y S, R1a representa R5a-Xa-Ba-X'a-, Ba representa un enlace directo o representa heterociclo o heteroarilo de 3 a 10 miembros, cada uno de los cuales tiene entre 1 y 4 heteroátomos seleccionados entre N, O y S, Xa y X'a representan, independientemente uno de otro, un enlace directo, o se seleccionan entre el grupo que comprende -NR6a-, -CO-, -CONR6a-, -CO2-, -OC(O)-, -S(O)ma-, -O-(CH2)ma-, -(CH2)ma-O-, -(CH2)ma-, -NR6aCO-, -(R6aO)2P(O)- y -NHCO2-, donde ma indica un numero que oscila entre 0 y 3, y R6a representa hidrogeno, alquilo o cicloalquilo, R5a representa hidrogeno, nitrilo, hidroxi, alquilo, alcoxi, cicloalquilo o arilo, o representa heterociclo o heteroarilo monocíclico o cíclico fusionado de 3 a 10 miembros, cada uno de los cuales tiene entre 1 y 3 heteroátomos seleccionados entre N, O y S y es opcionalmente sustituido por oxo o alquilo, o R5a y R6a pueden formar conjuntamente un ciclo de 4 a 8 miembros, R2a representa -(CR8aR9a)pa-Ya-R7a, pa indica un numero que oscila entre 0 y 2, R8a y R9a representan, independientemente uno de otro, hidrogeno o alquilo, o pueden formar conjuntamente un ciclo de 4 a 8 miembros, Ya representa un enlace directo o se selecciona entre el grupo que comprende -O-, -S-, -NR6a-, -NR6aC(O)-, -CO2-, -C(O)-, -C(O)NR6a-, -S(O)qa-, y -S(O)qaNR6a-, donde qa indica un numero que oscila entre 0 y 2; R7a representa hidrogeno, halogeno, ciano, hidroxi, nitro, alquilo, cicloalquilo o arilo, o representa heterociclo o heteroarilo de 3 a 10 miembros, cada uno de los cuales tiene entre 1 y 3 heteroátomos seleccionados entre N, S, y O y que opcionalmente contiene oxo, R3a representa hidrogeno, alquilo, -(CH2)qa-cicloalquilo o -(CH2)qa-heterociclo, R4a representa -(CH2)pa-Da-R10a, Da representa un enlace directo, representa cicloalquilo que opcionalmente contiene oxo, representa arilo, o representa heterociclo o heteroarilo de 3 a 10 miembros, cada uno de los cuales tiene entre 1 y 3 heteroátomos seleccionados entre N, S y O, R10a representa hidrogeno, halogeno, amino, ciano, nitro, hidroxi, alquilo, alquilcarbonilo, alquilsulfonilo o -(CH2)-NR8aR9a, donde alquilo, alcoxi, arilo, cicloalquilo, heterociclo y heteroarilo pueden ser opcionalmente sustituidos y los sustituyentes son uno o más seleccionados entre el grupo que comprende hidroxi, halogeno, nitrilo, amino, alquilamino, dialquilamino, alquilo, haloalquilo, alquilsulfonilo, carboxialquilo, alquilcarboniloxi, alquiltio, alquiloxicarbonilo, alquilaminocarbonilo, arilalcoxi y oxo; en la formula (2), nb indica un numero que oscila entre 1 y 3, mb indica 0 o 1, Ab representa un enlace directo, representa fenilo o representa un heteroarilo de 6 miembros que tiene entre 1 y 2 átomos de nitrogeno, Xb representa C o N, con la condicion de que mb sea 0 cuando Xb es N, y mb sea 1 cuando Xb es C, R1b representa hidrogeno, alquilo, -(CH2)rbNR7bR8b, o -(CH2)rbCO2H, donde rb indica un numero que oscila entre 1 y 5, y R7b y R8b representan, independientemente uno de otro hidrogeno, alquilo o alquilcarbonilo, o pueden formar conjuntamente una cadena de alquileno opcionalmente sustituida por alquilo donde opcionalmente un metileno es reemplazado por un átomo de N, R2b representa hidrogeno, halogeno, ciano, nitro, hidroxi, alquilo, alcoxi o trialquilsililo, representa -(CH2)pbCO2R7b, -(CH2)pbOR7b, -(CH2)pbNR7bR8b, -NHR10b, -N(H)S(O)2R7b, -NHC(O)R10b, --(CH2)pbS(O)2R7b o -CH2)pb-heterociclo-R10b, donde pb indica un numero que oscila entre 0 y 3, R7b y R8b son tal como se han definido anteriormente, R10b representa hidrogeno, oxo, alquilsulfonilo, alquilcarbonilo, alquiloxicarbonilo, alquilaminocarbonilo, alcoxi, alquilo o heterociclo, R3b representa hidrogeno, ciano, halogeno, alquilo o fenilo, o representa -(CH2)nb-heterociclo o -(CH2)nb-arilo, donde nb indica un numero que oscila entre 0 y 3, R4b representa -YbR11b, donde Yb representa un enlace directo o -(CR7bR8b)pbY'b-, donde pb indica un numero que oscila entre 0 y 3, R7b y R8b son tal como se han definido anteriormente, Y'b se selecciona entre el grupo que comprende -O-, -S-, -NR12b-, -NR12bC(O)-, -C(O)-, -C(O)O-, -C(O)NR12b-, -S(O)qb, y -S(O)qbNR12b-, donde R12b representa hidrogeno, alquilo, arilo o heteroarilo, qb indica un numero que oscila entre 0 y 2, R11b se selecciona entre el grupo que comprende hidrogeno, ciano, halogeno, hidroxi, tiol, carboxi, alquilo y -(CH2)tbBb-R13b, donde tb indica un numero que oscila entre 0 y 3, Bb representa heterociclo, heteroarilo o arilo, R13b representa hidrogeno, ciano, halogeno, hidroxi, oxo, tiol, carboxi, carboxialquilo, alquilcarboniloxi, alquilo, alcoxi, alquiltio, alquilcarbonilo o alquilsulfonilo, R5b representa hidrogeno, alquilo, cicloalquilo, heterociclo o heterociclilalquilo, R6b representa -(CR7bR8b)pb-Zb-Db-Wb-R14b, donde Zb representa un enlace directo o se selecciona entre el grupo que comprende -C(O)-, -C(O)O-, -C(O)NR12b-, y -S(O)yb-, yb indica un numero que es 1 o 2, Db representa un enlace directo o representa cicloalquilo, heteroarilo o heterociclo, Wb representa un enlace directo, o representa -NR7b-, -C(O)-, -C(O)O-, -C(O)NR12b-, -S(O)yb-, -S(O)ybNR12b- o -NR12bS(O)yb-, donde R14b representa hidrogeno, hidroxi, alquilo, alcoxi, heterociclo, heteroarilo, arilo o aralquilo, R5b y R6b conjuntamente representan una cadena de alquileno, donde alquilo, alcoxi, arilo, cicloalquilo, heterociclo y heteroarilo puede ser opcionalmente sustituidos, y los sustituyentes son uno o más seleccionados entre el grupo que comprende hidroxi, halogeno, nitrilo, amino, alquilamino, dialquilamino, carboxi, alquilo, alcoxi, carboxialquilo, alquilcarboniloxi, alquiltio, alquiloxicarbonilo, alquilaminocarbonilo, ariloalcoxi y oxo; en la formula (3) Bc representa arilo, o representa heterociclo o heteroarilo de 4-8 miembros, cada uno de los cuales tiene 1 o 2 heteroátomos seleccionados entre N, O y S, R7c representa hidrogeno, halogeno, hidroxi, nitrilo, nitro o alcoxi, R8c representa alquilo C1-6, cicloalquilo C3-8, heterociclilo, arilo, arilalquilo, cicloalquilo-alquilo o heterociclilo-alquilo, R9c representa hidrogeno, halogeno, hidroxi, nitrilo, nitro, alcoxi, aliloxi, alquilamino o arilamino, donde alquilo, alcoxi, arilo, cicloalquilo, heterociclo y heteroarilo pueden ser opcionalmente sustituidos, y los sustituyentes son uno o más seleccionados entre el grupo que comprende hidroxi, halogeno, nitrilo, amino, alquilamino C1-6, di(alquilo C1-6)amino, carboxi, alquilo C1-6, halogeno-alquilo C1-6, alcoxi C1-6, arilo-alcoxi C1-6 y oxo.
ARP100103924A 2009-10-26 2010-10-26 Composicion farmaceutica que comprende un compuesto indol AR078775A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090101978 2009-10-26
KR20100098511 2010-10-08

Publications (1)

Publication Number Publication Date
AR078775A1 true AR078775A1 (es) 2011-11-30

Family

ID=43922791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103924A AR078775A1 (es) 2009-10-26 2010-10-26 Composicion farmaceutica que comprende un compuesto indol

Country Status (12)

Country Link
US (2) US20120214804A1 (es)
EP (1) EP2493469A4 (es)
JP (1) JP5820813B2 (es)
KR (1) KR101325272B1 (es)
CN (1) CN102596198B (es)
AR (1) AR078775A1 (es)
BR (1) BR112012009894A2 (es)
MX (1) MX338807B (es)
RU (1) RU2557243C2 (es)
TR (1) TR201204895T1 (es)
TW (2) TW201119651A (es)
WO (1) WO2011052950A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101304772B1 (ko) * 2011-04-11 2013-09-05 인제대학교 산학협력단 ＮｅｃｒｏＸ―５를 유효성분으로 포함하는 미토콘드리아 기능 조절용 조성물
KR101400346B1 (ko) * 2012-01-31 2014-05-30 인제대학교 산학협력단 ＮｅｃｒｏＸ를 함유하는 암 전이 억제용 조성물
WO2013115457A1 (ko) * 2012-01-31 2013-08-08 인제대학교 산학협력단 ＮｅｃｒｏＸ를 함유하는 암 전이 억제용 조성물
RU2664696C2 (ru) * 2014-04-18 2018-08-21 ЭлДжи КЕМ, ЛТД. Композиция для предотвращения или лечения жировых болезней печени
JP2017520553A (ja) * 2014-06-30 2017-07-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 加齢関連症状及び疾患を治療するためのケト酪酸化合物ならびに組成物
KR101633703B1 (ko) * 2014-12-30 2016-06-27 한국원자력의학원 necro X-5를 유효성분으로 포함하는 방사선 조사에 의한 세포손상 예방 또는 치료용 조성물
CN107434819B (zh) * 2017-02-15 2020-03-17 河北医科大学第二医院 吲哚-tempo缀合物及其在保护远隔器官对抗缺血再灌注损伤中的用途
JP7069295B2 (ja) 2017-08-17 2022-05-17 エックスダブリューファルマ リミテッド 活性酸素種スカベンジャー誘導体の調製および使用
ES2947741T3 (es) 2017-09-04 2023-08-17 Xwpharma Ltd Preparación y uso de un barredor de especies reactivas de oxígeno
US11795147B2 (en) 2019-08-26 2023-10-24 Boehringer Ingelheim International Gmbh Modulators of complex I
US20240009202A1 (en) 2020-08-19 2024-01-11 Mitoimmune Therapeutics Inc. Mitochondria-targeted antioxidant as agent for treating pathologic inflammation caused by mabc-r infection
KR20220141251A (ko) 2021-04-12 2022-10-19 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민의 신규 결정형
WO2022220518A1 (ko) 2021-04-12 2022-10-20 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민 황산염 및 이의 신규 결정형
KR20230140401A (ko) * 2022-03-25 2023-10-06 주식회사 미토이뮨테라퓨틱스 항바이러스용 약학적 조성물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
CA2302402C (en) * 1997-09-05 2008-12-02 Lead Chemical Co., Ltd. Stereoisomeric indole compounds, process for the preparation of the same, and use thereof
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
IL130169A (en) * 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US20060160748A1 (en) * 2003-11-25 2006-07-20 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1877044A4 (en) * 2005-04-21 2009-09-02 Glenn A Goldstein AMIDE N-ACETYLCYSTEINE (AMIDE NAC) FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH OXIDATIVE STRESS
US20070161609A1 (en) * 2006-01-10 2007-07-12 Charles Buck Use of mitochondrially targeted antioxidant in treatment and prevention of drug-induced liver disease
US8436038B2 (en) * 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
JP5364103B2 (ja) * 2007-12-20 2013-12-11 エルジー・ライフ・サイエンシーズ・リミテッド グルコキナーゼ活性化剤およびそれを活性成分として含有する医薬組成物
CN101952281B (zh) 2008-01-04 2014-04-02 株式会社Lg生命科学 具有细胞、组织及器官保存效果的吲哚及吲唑衍生物

Also Published As

Publication number Publication date
JP5820813B2 (ja) 2015-11-24
CN102596198A (zh) 2012-07-18
US20120214804A1 (en) 2012-08-23
WO2011052950A3 (en) 2011-11-24
US10322135B2 (en) 2019-06-18
RU2557243C2 (ru) 2015-07-20
RU2012121815A (ru) 2013-12-10
BR112012009894A2 (pt) 2016-11-29
EP2493469A2 (en) 2012-09-05
TW201119651A (en) 2011-06-16
JP2013508452A (ja) 2013-03-07
KR101325272B1 (ko) 2013-11-05
WO2011052950A2 (en) 2011-05-05
MX2012004504A (es) 2012-09-07
US20170165272A1 (en) 2017-06-15
TWI535440B (zh) 2016-06-01
KR20110046321A (ko) 2011-05-04
MX338807B (es) 2016-05-02
EP2493469A4 (en) 2013-05-29
TR201204895T1 (tr) 2013-01-21
CN102596198B (zh) 2016-01-27
TW201414473A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
AR078775A1 (es) Composicion farmaceutica que comprende un compuesto indol
JP2011523651A5 (es)
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20140038A1 (es) Compuestos antivirales
JP2013533317A5 (es)
AR079026A1 (es) Antagonistas de espiro -oxindol de mdm2
JP2011521965A5 (es)
AR089910A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas
AR067176A1 (es) Compuesto de benzazepina y preparacion farmaceutica
PE20070221A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR067977A1 (es) Derivados de piridina y su uso como inmunomoduladores
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
JP2012512169A5 (es)
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
JP2012511004A5 (es)
PE20071080A1 (es) Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR086367A1 (es) Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka
JP2012504132A5 (es)
JP2010510233A5 (es)
NZ601220A (en) Hepatitis c virus inhibitors
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
RU2008116674A (ru) Новые циклические пептидные соединения

Legal Events

Date Code Title Description
FC Refusal